Journal: Inflammation

Article Title: The Influenza-Induced Pulmonary Inflammatory Exudate in Susceptible Tpl2-Deficient Mice Is Dictated by Type I IFN Signaling.

doi: 10.1007/s10753-022-01736-8

Figure Lengend Snippet: Fig. 5 Anti-Ly6G treatment is only modestly beneficial for influenza-infected Ifnar1−/−Tpl2−/− mice. Mice were infected intranasally with 104 pfu of influenza A/x31. They were administered either 200 μg isotype control antibody (clone 2A3#BE0089, BioXCell, red line), 200 μg anti-Ly6G antibody (clone 1A8 #BE0075-1, BioXCell, grey line), or 2.5 μg neutralizing anti-IFNλ2/3 antibody (clone 244716 #MAB17892, R&D Systems, dashed black line) intraperitoneally in 200 μl on days 5 and 7 post-infection. Their weight change (A) and clinical scores (B) were recorded daily. Survival (C) was assessed through 12 dpi. Numbers of mice: Ifnar1−/−Tpl2−/− treated with isotype control (n = 4) mice, Ifnar1−/−Tpl2−/− treated with anti-IFNλ2/3 (n = 3), and Ifnar1−/−Tpl2−/− treated with anti-Ly6G (n = 5). Mean and SEM are shown. Data are pooled from 2 independent experiments. Log-rank Mantel-Cox test was used for statistics.

Article Snippet: On days 5 and 7 post infection, the mice were administered intraperitoneally (i.p.) either 200 μg isotype control antibody (clone 2A3#BE0089, BioXCell), 200 μg anti-Ly6G antibody (clone 1A8 #BE0075-1, BioXCell), or 2.5 μg anti-IFN-λ2/3 antibody (clone 244,716 #MAB17892, R&D Systems).

Techniques: Infection, Control